Printer Friendly

OPG, DU PONT MERCK TO DEVELOP, MARKET MULTI-SOURCE DRUGS

 OPG, DU PONT MERCK TO DEVELOP, MARKET MULTI-SOURCE DRUGS
 WILMINGTON, Del., April 6 /PRNewswire/ -- OPG and The Du Pont Merck Pharmaceutical Company announced today they are cooperating in the marketing and development of multi-source pharmaceutical products.
 Du Pont Merck's Multi-Source Products Division and OPG's Pharmachemie had previously signed a number of agreements in 1991 covering the distribution by the Multi-Source Products Division of products from Pharmachemie in the United States, Canada and Europe. They are continuing these arrangements with mutual development of multi- source products for marketing on a global basis. The companies have also agreed to set up a joint marketing operation in the United Kingdom in 1992.
 Du Pont Merck, a company owned by Du Pont (NYSE: DD) and Merck & Co., Inc. (NYSE: MRK), Rahway, N.J., with operations in the United States, Canada and Europe, is engaged in the development, manufacture and sales of pharmaceutical products. Du Pont Merck's Multi-Source Products Division markets a broad line of products manufactured by the company itself or acquired from third parties.
 OPG is a group of companies providing an extensive range of products and services to a variety of segments of the healthcare market. The Dutch market has been its primary target for a long period of time, and OPG is currently increasing its activities outside The Netherlands. Pharmachemie, a Dutch pharmaceutical company founded in 1946, is wholly owned by OPG. Pharmachemie manufactures and markets a wide array of generic pharmaceutical products in The Netherlands and a range of anti- cancer products in over 40 countries in the world, including the USA. In 1990, the company occupied a totally new, highly automated factory of revolutionary design.
 /delval/
 -0- 4/6/92
 /CONTACT: Roger Morris of Du Pont Merck, 302-992-4747/
 (DD MRK) CO: OPG; The Du Pont Merck Pharmaceutical Company ST: Delaware IN: MTC SU: JVN


MK -- PH009 -- 5276 04/06/92 10:17 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Apr 6, 1992
Words:314
Previous Article:FLUOR DANIEL AWARDED CONTRACT BY MERCK
Next Article:GREEN MACHINE NETWORK REPORTS RECORD GROWTH FOR 1991


Related Articles
DU PONT MERCK EXPANDS ALZHEIMER DRUG TRIAL
DU PONT MERCK CEO RECEIVES HONORARY DOCTORATE
DU PONT MERCK APPOINTS TWO R&D VICE PRESIDENTS
DU PONT MERCK, BANYU PLAN JOINT VENTURE FOR JAPAN
MERCK TO LICENSE TRADEMARK AND MARKETING RIGHTS FOR TWO BRANDS TO THE DU PONT MERCK PHARMACEUTICAL COMPANY AND ITS EUROPEAN SUBSIDIARIES
ROBERTS PHARMACEUTICAL COMPLETES ACQUISITION OF ETHMOZINE FROM DU PONT MERCK
BOC HEALTH CARE ACQUIRES BREVIBLOC FROM DU PONT MERCK
THE DU PONT MERCK PHARMACEUTICAL COMPANY DISPUTES SENATE PRICING ALLEGATIONS
THE DU PONT MERCK PHARMACEUTICAL COMPANY AND BRITISH TECHNOLOGY GROUP USA SIGN AGREEMENT TO TRANSFER PHARMACEUTICAL TECHNOLOGIES
DU PONT MERCK WILL CO-PROMOTE NEW WELLCOME EPILEPSY DRUG

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters